Therapy
Biotechnology
Health

Intellia Therapeutics

$16.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.10 (0.59%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell NTLA and other stocks, options, ETFs, and crypto commission-free!

About

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. Read More The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Employees
211
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
762.48M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
740.67K
High Today
$17.26
Low Today
$16.76
Open Price
$16.98
Volume
220.21K
52 Week High
$32.95
52 Week Low
$11.03

Collections

Therapy
Biotechnology
Health
Medical
Technology
2016 IPO
US
North America

News

Simply Wall StMar 12

If You Had Bought Intellia Therapeutics (NASDAQ:NTLA) Stock A Year Ago, You’d Be Sitting On A 50% Loss, Today

Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders should be happy to see the share price up 23% in the last month. But that’s not enough to compensate for the decline over the last twelve months. Like a receding glacier in a warming world, the share price has melted 50% in that period. The share price recovery is not so impressive when you consider the fall. Of course, it could be that the fall was overdone. See our latest analysis for Intellia Therapeutics Intellia Therapeutics isn’t a profitable co...

1,113
MarketBeatMar 3

Stock Price, News, & Analysis for Intellia Therapeutics

News coverage about NTLA stock has trended somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Intellia Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of ...

9
Yahoo FinanceMar 1

Intellia CEO not involved in Starboard's Bristol-Myers board challenge

FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau/File Photo By Greg Roumeliotis NEW YORK (Reuters) - Intellia Therapeutics Inc Chief Executive John Leonard, who U.S. drug maker Bristol-Myers Squibb Co said last week was nominated by hedge fund Starboard Value LP to sit on its board, is not affiliated with the effort, an Intellia spokeswoman said on Thursday. "He is not...

29

Earnings

-$0.61
-$0.55
-$0.48
-$0.42
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 30, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.